Cheshire, UK -- (MARKET WIRE) -- November 30, 2006 --
Protherics PLC
Notification of Major Interest in Shares
London, UK; Brentwood, TN; 30 November 2006 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, on 29 November 2006, it received notification
from Aviva plc that, as at 27 November 2006, Aviva plc and its subsidiaries held
an interest in 31,441,191 ordinary shares, representing 12.02% of the issued
share capital of the Company
The Shares are represented by a beneficial interest in 17,502,185 ordinary
shares (6.69%) and a non-beneficial interest in 13,939,006 ordinary shares
(5.33%).
This notification follows the purchase of 105,500 ordinary shares on 27 November
2006 representing 0.04% of the issued share capital of the Company.
The issued share capital of the Company is 261,487,953 ordinary shares.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, David Yates +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange